Latvian
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Rasilamlo (aliskiren / amlodipine) - C09XA53

Updated on site: 09-Oct-2017

Zāļu nosaukumsRasilamlo
ATĶ kodsC09XA53
Vielaaliskiren / amlodipine
RažotājsNovartis Europharm Ltd
Rasilamlo
EMA/101161/2015
EMEA/H/C/002073
EPAR summary for the public

How is Rasilamlo used?

The patient should take one tablet once a day with a light meal, preferably at the same time each day. The tablet should be swallowed whole with water. It should not be taken together with fruit juice or drinks containing plant extracts such as herbal teas.

The strength of the tablet the patient takes depends on the doses of aliskiren or amlodipine that they received previously. The dose may be adjusted based on the side effects the patient experienced with their previous treatment with aliskiren or amlodipine and also on how the patient responds to treatment with Rasilamlo.

Rasilamlo can be used with other antihypertensive medicines, with the exception of ‘angiotensin converting enzyme (ACE) inhibitors’ or ‘angiotensin receptor blockers’ (ARBs) in patients with diabetes, or moderate or severe kidney impairment.

How does Rasilamlo work?

Rasilamlo contains two active substances, aliskiren and amlodipine.

Aliskiren is a renin inhibitor. It blocks the activity of a human enzyme called renin, which is involved in the production of a substance called angiotensin I in the body. Angiotensin I is converted into the hormone angiotensin II, which is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the production of angiotensin I, levels of both angiotensin I and angiotensin II fall. This causes vasodilation (widening of the blood vessels), so that the blood pressure drops.

Amlodipine is a calcium channel blocker. It blocks special channels on the surface of cells called calcium channels, through which calcium ions normally enter. When calcium ions enter the cells in the

In three main studies involving 2,212 patients Rasilamlo was compared with aliskiren or amlodipine

Rasilamlo was more effective atvairscontrolling e e tial hypertension than placebo, aliskiren or amlodipine used alone.

In the first study, patients taking R s l mlo 300/10 mg and 300/5 mg had a fall in their sitting diastolic blood pressure of 13.1 mmHg and 10.5 mmHg, respectively, compared with a fall of 5.8 mmHg in patients taking aliskiren 300lesmg.

In the second study the fa s in blood pressure were 11.0 mmHg and 9.0 mmHg with Rasilamlo 300/10 mg and 150/10mg,ā respectively, compared with 7.2mmHg with amlodipine 10 mg.

The third study showedZ a fall in blood pressure of 8.5 mmHg with Rasilamlo 150/5 mg compared with 8.0 mmHg and 4.8 mmHg with amlodipine 10 mg and 5 mg, respectively.

What is the risk associated with Rasilamlo?

The most common side effects with Rasilamlo are hypotension (low blood pressure) and peripheral oedema (swelling, especially of the ankles and feet). For the full list of all side effects reported with Rasilamlo, see the package leaflet.

Rasilamlo must not be used in people who are hypersensitive (allergic) to aliskiren, amlodipine, to any of the other ingredients of the medicine or other substances derived from dihydropyridine (a group that includes amlodipine). It must not be used in patients with a history of angioedema (swelling beneath the skin) with aliskiren, hereditary angioedema or angioedema of no obvious cause, severe hypotension, shock, narrowing of the aortic heart valve or in patients with heart failure after a heart

Rasilamlo EMA/101161/2015
āles Z

attack. It must also not be used in women who are more than three months pregnant or in patients taking medicines containing ciclosporin, itraconazole or other medicines known as ‘potent P- glycoprotein inhibitors’ (such as quinidine). Rasilamlo in combination with an ACE inhibitor or an ARB must not be used in patients with diabetes, or moderate or severe kidney impairment. Rasilamlo is for use in adults only; it must not be used in children aged less than 2 years and is not recommended for older children.

Why has Rasilamlo been approved?

The CHMP decided that Rasilamlo’s benefits are greater than its risks and recommended that it be given marketing authorisation.

What measures are being taken to ensure the safe and effective use of Rasilamlo?

A risk management plan has been developed to ensure that Rasilamlo is used as afely as possible. Based on this plan, safety information has been included in the summary of product characteristics and

medicine/Human medicines/European Public Assessment Reports. For more information about

Komentārus

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Palīdzība
  • Get it on Google Play
  • Par
  • Info on site by:

  • Presented by RXed.eu

  • 27558

    recepšu zāles uzskaitītas